VisEn Medical Inc. acquired a 45-patent portfolio and related fluorescent imaging agent platforms from German giant Bayer Schering Pharma AG for an undisclosed amount.
The Bedford, Mass.-based imaging systems maker said it will integrate its newly acquired intellectual property into its own programs. The deal takes VisEn’s portfolio of fluorescent imaging agent patents to more than 150 worldwide.
VisEn said the new patents cover "physiologic agents, bioconjugates and targeted fluorescence agents, and certain activatable imaging agents for measurement of diverse biomarker activity in living systems." The company also said it plans to expand its preclinical and clinical imaging agent pipelines.
"The acquisition of these assets significantly expands VisEn’s patent coverage of in vivo fluorescent imaging agents, and adds to our R&D capability and pipeline of preclinical agent products and clinical imaging agents going forward," president and CEO Kirtland Poss said in a prepared statement.